145 results on '"Koch, B.C.P."'
Search Results
2. Quantification of cefuroxime and flucloxacillin in synovial tissue and bone using ultra-performance convergence chromatography-tandem mass spectrometry
- Author
-
Bahmany, S., Holst, A., Hoogendoorn, M.H., Oosterhoff, M., van Oldenrijk, J., Bos, P.K., Veltman, E.S., and Koch, B.C.P.
- Published
- 2024
- Full Text
- View/download PDF
3. Reply to ‘optimizing treatment outcomes: integrating antihypertensive drug concentration measurement, personalized feedback, and psychosocial factors in resistant hypertension’
- Author
-
Peeters, L.E.J., primary, Koch, B.C.P., additional, and Versmissen, J., additional
- Published
- 2024
- Full Text
- View/download PDF
4. Quantification of vancomycin and clindamycin in human plasma and synovial fluid applying ultra-performance liquid chromatography tandem mass spectrometry
- Author
-
Ringeling, L.T., Bahmany, S., van Oldenrijk, J., Bos, P.K., Veltman, E.S., and Koch, B.C.P.
- Published
- 2022
- Full Text
- View/download PDF
5. Quantification of beta-lactam antibiotics cefuroxime and flucloxacillin in human synovial fluid, using ultra-performance convergence chromatography-tandem mass spectrometry
- Author
-
Demir, Z., Bahmany, S., Bethlehem, C., van Oldenrijk, J., Bos, P.K., and Koch, B.C.P.
- Published
- 2021
- Full Text
- View/download PDF
6. The effectiveness of nitrofurantoin, fosfomycin and trimethoprim for the treatment of cystitis in relation to renal function
- Author
-
ten Doesschate, T., van Haren, E., Wijma, R.A., Koch, B.C.P., Bonten, M.J.M., and van Werkhoven, C.H.
- Published
- 2020
- Full Text
- View/download PDF
7. Lessons learned from conducting a randomized controlled trial to improve non-adherence to antihypertensive drug treatment
- Author
-
Peeters, L.E.J., primary, van Gelder, T., additional, van Dijk, L., additional, Koch, B.C.P., additional, and Versmissen, J., additional
- Published
- 2023
- Full Text
- View/download PDF
8. Exploring P-gp as moderator of side effects and effectiveness of risperidone in children and adolescents
- Author
-
Hermans, R.A., Gangapersad, R.N., Kloosterboer, S.M., van Schaik, R.H.N., Hillegers, M.H.J., Koch, B.C.P., de Winter, B.C.M., and Dierckx, B.
- Published
- 2024
- Full Text
- View/download PDF
9. High interindividual variability in urinary fosfomycin concentrations in healthy female volunteers
- Author
-
Wijma, R.A., Koch, B.C.P., van Gelder, T., and Mouton, J.W.
- Published
- 2018
- Full Text
- View/download PDF
10. Formulating a poorly water soluble drug into an oral solution suitable for paediatric patients; lorazepam as a model drug
- Author
-
van der Vossen, A.C., van der Velde, I., Smeets, O.S.N.M., Postma, D.J., Eckhardt, M., Vermes, A., Koch, B.C.P., Vulto, A.G., and Hanff, L.M.
- Published
- 2017
- Full Text
- View/download PDF
11. The BAF complex inhibitor pyrimethamine reverses HIV-1 latency in people with HIV-1 on antiretroviral therapy.
- Author
-
Prins, H.A., Crespo, R., Lungu, C., Rao, S., Li, L, Overmars, R.J., Papageorgiou, G., Mueller, Y.M., Stoszko, M., Hossain, T., Kan, T.W., Rijnders, B.J.A., Bax, H.I., Gorp, E.C. van, Nouwen, J.L., Vries-Sluijs, T.E.M.S. De, Schurink, C.A.M., Mendonça Melo, M. de, Nood, E. van, Colbers, A., Burger, D.M., Palstra, R.J., Kampen, J. J. A. van, Vijver, D.A. van de, Mesplède, T., Katsikis, P.D., Gruters, R.A., Koch, B.C.P., Verbon, A., Mahmoudi, T., Rokx, C., Prins, H.A., Crespo, R., Lungu, C., Rao, S., Li, L, Overmars, R.J., Papageorgiou, G., Mueller, Y.M., Stoszko, M., Hossain, T., Kan, T.W., Rijnders, B.J.A., Bax, H.I., Gorp, E.C. van, Nouwen, J.L., Vries-Sluijs, T.E.M.S. De, Schurink, C.A.M., Mendonça Melo, M. de, Nood, E. van, Colbers, A., Burger, D.M., Palstra, R.J., Kampen, J. J. A. van, Vijver, D.A. van de, Mesplède, T., Katsikis, P.D., Gruters, R.A., Koch, B.C.P., Verbon, A., Mahmoudi, T., and Rokx, C.
- Abstract
Contains fulltext : 291084.pdf (Publisher’s version ) (Open Access), Reactivation of the latent HIV-1 reservoir is a first step toward triggering reservoir decay. Here, we investigated the impact of the BAF complex inhibitor pyrimethamine on the reservoir of people living with HIV-1 (PLWH). Twenty-eight PLWH on suppressive antiretroviral therapy were randomized (1:1:1:1 ratio) to receive pyrimethamine, valproic acid, both, or no intervention for 14 days. The primary end point was change in cell-associated unspliced (CA US) HIV-1 RNA at days 0 and 14. We observed a rapid, modest, and significant increase in (CA US) HIV-1 RNA in response to pyrimethamine exposure, which persisted throughout treatment and follow-up. Valproic acid treatment alone did not increase (CA US) HIV-1 RNA or augment the effect of pyrimethamine. Pyrimethamine treatment did not result in a reduction in the size of the inducible reservoir. These data demonstrate that the licensed drug pyrimethamine can be repurposed as a BAF complex inhibitor to reverse HIV-1 latency in vivo in PLWH, substantiating its potential advancement in clinical studies.
- Published
- 2023
12. Design and stability study of an oral solution of amlodipine besylate for pediatric patients
- Author
-
van der Vossen, A.C., van der Velde, I., Smeets, O.S.N.M., Postma, D.J., Vermes, A., Koch, B.C.P., Vulto, A.G., and Hanff, L.M.
- Published
- 2016
- Full Text
- View/download PDF
13. The pharmacokinetics and toxicity of morning vs. evening tobramycin dosing for pulmonary exacerbations of cystic fibrosis: A randomised comparison
- Author
-
Prayle, A.P., Jain, K., Touw, D.J., Koch, B.C.P., Knox, A.J., Watson, A., and Smyth, A.R.
- Published
- 2016
- Full Text
- View/download PDF
14. The BAF complex inhibitor pyrimethamine reverses HIV-1 latency in people with HIV-1 on antiretroviral therapy
- Author
-
Prins, H.A.B., primary, Crespo, R., additional, Lungu, C., additional, Rao, S., additional, Li, L., additional, Overmars, R.J., additional, Papageorgiou, G., additional, Mueller, Y.M., additional, Hossain, T., additional, Kan, T.W., additional, Rijnders, B.J.A., additional, Bax, H.I., additional, van Gorp, E.C.M., additional, Nouwen, J.L., additional, de Vries-Sluijs, T.E.M.S., additional, Schurink, C.A.M., additional, de Mendonça Melo, M., additional, van Nood, E., additional, Colbers, A., additional, Burger, D., additional, Palstra, R-J., additional, van Kampen, J.J.A., additional, van de Vijver, D.A.M.C., additional, Mesplède, T., additional, Katsikis, P.D., additional, Gruters, R.A., additional, Koch, B.C.P., additional, Verbon, A., additional, Mahmoudi, T., additional, and Rokx, C., additional
- Published
- 2022
- Full Text
- View/download PDF
15. Pooled Population Pharmacokinetic Analysis for Exploring Ciprofloxacin Pharmacokinetic Variability in Intensive Care Patients
- Author
-
Guo, T., Abdulla, A., Koch, B.C.P., Hassel, J.G.C. van, Endeman, H., Schouten, J.A., Elbers, P.W.G., Brüggeman, R.J.M., Hest, R.M., Pharmacy, Intensive Care, Medical Microbiology & Infectious Diseases, Intensive care medicine, ACS - Diabetes & metabolism, Amsterdam Cardiovascular Sciences, and AGEM - Amsterdam Gastroenterology Endocrinology Metabolism
- Subjects
Pharmacology ,lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4] ,Pharmacology (medical) - Abstract
Contains fulltext : 252099.pdf (Publisher’s version ) (Open Access) BACKGROUND AND OBJECTIVE: Previous pharmacokinetic (PK) studies of ciprofloxacin in intensive care (ICU) patients have shown large differences in estimated PK parameters, suggesting that further investigation is needed for this population. Hence, we performed a pooled population PK analysis of ciprofloxacin after intravenous administration using individual patient data from three studies. Additionally, we studied the PK differences between these studies through a post-hoc analysis. METHODS: Individual patient data from three studies (study 1, 2, and 3) were pooled. The pooled data set consisted of 1094 ciprofloxacin concentration-time data points from 140 ICU patients. Nonlinear mixed-effects modeling was used to develop a population PK model. Covariates were selected following a stepwise covariate modeling procedure. To analyze PK differences between the three original studies, random samples were drawn from the posterior distribution of individual PK parameters. These samples were used for a simulation study comparing PK exposure and the percentage of target attainment between patients of these studies. RESULTS: A two-compartment model with first-order elimination best described the data. Inter-individual variability was added to the clearance, central volume, and peripheral volume. Inter-occasion variability was added to clearance only. Body weight was added to all parameters allometrically. Estimated glomerular filtration rate on ciprofloxacin clearance was identified as the only covariate relationship resulting in a drop in inter-individual variability of clearance from 58.7 to 47.2%. In the post-hoc analysis, clearance showed the highest deviation between the three studies with a coefficient of variation of 14.3% for posterior mean and 24.1% for posterior inter-individual variability. The simulation study showed that following the same dose regimen of 400 mg three times daily, the area under the concentration-time curve of study 3 was the highest with a mean area under the concentration-time curve at 24 h of 58 mg·h/L compared with that of 47.7 mg·h/L for study 1 and 47.6 mg·h/L for study 2. Similar differences were also observed in the percentage of target attainment, defined as the ratio of area under the concentration-time curve at 24 h and the minimum inhibitory concentration. At the epidemiological cut-off minimum inhibitory concentration of Pseudomonas aeruginosa of 0.5 mg/L, percentage of target attainment was only 21%, 18%, and 38% for study 1, 2, and 3, respectively. CONCLUSIONS: We developed a population PK model of ciprofloxacin in ICU patients using pooled data of individual patients from three studies. A simple ciprofloxacin dose recommendation for the entire ICU population remains challenging owing to the PK differences within ICU patients, hence dose individualization may be needed for the optimization of ciprofloxacin treatment.
- Published
- 2022
16. Pooled Population Pharmacokinetic Analysis for Exploring Ciprofloxacin Pharmacokinetic Variability in Intensive Care Patients
- Author
-
Guo, Tingjie, Abdulla, A., Koch, B.C.P., Hasselt, J.G. van, Endeman, H., Schouten, J.A., Elbers, P.W.G., Brüggemann, R.J.M., Hest, R.M. van, Guo, Tingjie, Abdulla, A., Koch, B.C.P., Hasselt, J.G. van, Endeman, H., Schouten, J.A., Elbers, P.W.G., Brüggemann, R.J.M., and Hest, R.M. van
- Abstract
Item does not contain fulltext, BACKGROUND AND OBJECTIVE: Previous pharmacokinetic (PK) studies of ciprofloxacin in intensive care (ICU) patients have shown large differences in estimated PK parameters, suggesting that further investigation is needed for this population. Hence, we performed a pooled population PK analysis of ciprofloxacin after intravenous administration using individual patient data from three studies. Additionally, we studied the PK differences between these studies through a post-hoc analysis. METHODS: Individual patient data from three studies (study 1, 2, and 3) were pooled. The pooled data set consisted of 1094 ciprofloxacin concentration-time data points from 140 ICU patients. Nonlinear mixed-effects modeling was used to develop a population PK model. Covariates were selected following a stepwise covariate modeling procedure. To analyze PK differences between the three original studies, random samples were drawn from the posterior distribution of individual PK parameters. These samples were used for a simulation study comparing PK exposure and the percentage of target attainment between patients of these studies. RESULTS: A two-compartment model with first-order elimination best described the data. Inter-individual variability was added to the clearance, central volume, and peripheral volume. Inter-occasion variability was added to clearance only. Body weight was added to all parameters allometrically. Estimated glomerular filtration rate on ciprofloxacin clearance was identified as the only covariate relationship resulting in a drop in inter-individual variability of clearance from 58.7 to 47.2%. In the post-hoc analysis, clearance showed the highest deviation between the three studies with a coefficient of variation of 14.3% for posterior mean and 24.1% for posterior inter-individual variability. The simulation study showed that following the same dose regimen of 400 mg three times daily, the area under the concentration-time curve of study 3 was the highest with a mean a
- Published
- 2022
17. [OP.2B.01] DEVELOPMENT OF A DRIED BLOOD SPOT (DBS) BASED MEASUREMENT OF ANTIHYPERTENSIVE DRUG LEVELS TO ASSESS ADHERENCE
- Author
-
Hameli, E., Heijnen, C.W., Bahmany, S., Van Der Nagel, B.C.H., Van Den Meiracker, A.H., Van Gelder, T., Koch, B.C.P., and Versmissen, J.
- Published
- 2017
- Full Text
- View/download PDF
18. The Oral Bioavailability and Metabolism of Midazolam in Stable Critically Ill Children: A Pharmacokinetic Microtracing Study
- Author
-
Groen, B.D. van, Krekels, E.H.J., Mooij, M.G., Duijn, E. van, Vaes, W.H., Windhorst, A.D., Rosmalen, J. van, Hartman, S.J.F., Hendrikse, N.H., Koch, B.C.P., Allegaert, K., Tibboel, D., Knibbe, C.A.J., Wildt, S.N. de, Groen, B.D. van, Krekels, E.H.J., Mooij, M.G., Duijn, E. van, Vaes, W.H., Windhorst, A.D., Rosmalen, J. van, Hartman, S.J.F., Hendrikse, N.H., Koch, B.C.P., Allegaert, K., Tibboel, D., Knibbe, C.A.J., and Wildt, S.N. de
- Abstract
Contains fulltext : 232102.pdf (Publisher’s version ) (Open Access), Midazolam is metabolized by the developmentally regulated intestinal and hepatic drug-metabolizing enzyme cytochrome P450 (CYP) 3A4/5. It is frequently administered orally to children, yet knowledge is lacking on the oral bioavailability in term neonates up until 1 year of age. Furthermore, the dispositions of the major metabolites 1-OH-midazolam (OHM) and 1-OH-midazolam-glucuronide (OHMG) after oral administration are largely unknown for the entire pediatric age span. We aimed to fill these knowledge gaps with a pediatric [(14) C]midazolam microtracer population pharmacokinetic study. Forty-six stable, critically ill children (median age 9.8 (range 0.3-276.4) weeks) received a single oral [(14) C]midazolam microtracer (58 (40-67) Bq/kg) when they received a therapeutic continuous intravenous midazolam infusion and had an arterial line in place enabling blood sampling. For midazolam, in a one-compartment model, bodyweight was a significant predictor for clearance (0.98 L/hour) and volume of distribution (8.7 L) (values for a typical individual of 5 kg). The typical oral bioavailability in the population was 66% (range 25-85%). The exposures of OHM and OHMG were highest for the youngest age groups and significantly decreased with postnatal age. The oral bioavailability of midazolam, largely reflective of intestinal and hepatic CYP3A activity, was on average lower than the reported 49-92% for preterm neonates, and higher than the reported 21% for children> 1 year of age and 30% for adults. As midazolam oral bioavailability varied widely, systemic exposure of other CYP3A-substrate drugs after oral dosing in this population may also be unpredictable, with risk of therapy failure or toxicity.
- Published
- 2021
19. Chloroquine for treatment of COVID-19 results in subtherapeutic exposure and prolonged QTc intervals
- Author
-
Brüggemann, R.J.M., Moes, D., Rhee, K.P. van, Veer, N.E. van 't, Koch, B.C.P., Rossum, M. van, Windsant-van den Tweel, A.V., Reijers, M.H., Kimmenade, R.R. van, Rahamat-Langendoen, J.C., Rettig, T.C., Raalte, R. van, Paassen, J. van, Polderman, F.N., Linden, P.D. van der, Frenzel, T., Mast, Q. de, Burger, D.M., Schouten, J.A., Veerdonk, F.L. van de, Pickkers, P., Heine, R. ter, Brüggemann, R.J.M., Moes, D., Rhee, K.P. van, Veer, N.E. van 't, Koch, B.C.P., Rossum, M. van, Windsant-van den Tweel, A.V., Reijers, M.H., Kimmenade, R.R. van, Rahamat-Langendoen, J.C., Rettig, T.C., Raalte, R. van, Paassen, J. van, Polderman, F.N., Linden, P.D. van der, Frenzel, T., Mast, Q. de, Burger, D.M., Schouten, J.A., Veerdonk, F.L. van de, Pickkers, P., and Heine, R. ter
- Abstract
Item does not contain fulltext
- Published
- 2021
20. The bioavailability and maturing clearance of doxapram in preterm infants
- Author
-
Flint, R.B., Simons, S.H., Andriessen, P., Liem, K.D., Degraeuwe, P.L.J., Reiss, I.K.M., Heine, R. ter, Engbers, A.G.J., Koch, B.C.P., Groot, R. de, Burger, D.M., Knibbe, C.A.J., Völler, S., Flint, R.B., Simons, S.H., Andriessen, P., Liem, K.D., Degraeuwe, P.L.J., Reiss, I.K.M., Heine, R. ter, Engbers, A.G.J., Koch, B.C.P., Groot, R. de, Burger, D.M., Knibbe, C.A.J., and Völler, S.
- Abstract
Contains fulltext : 234074.pdf (Publisher’s version ) (Closed access), BACKGROUND: Doxapram is used for the treatment of apnea of prematurity in dosing regimens only based on bodyweight, as pharmacokinetic data are limited. This study describes the pharmacokinetics of doxapram and keto-doxapram in preterm infants. METHODS: Data (302 samples) from 75 neonates were included with a median (range) gestational age (GA) 25.9 (23.9-29.4) weeks, bodyweight 0.95 (0.48-1.61) kg, and postnatal age (PNA) 17 (1-52) days at the start of continuous treatment. A population pharmacokinetic model was developed using non-linear mixed-effects modelling (NONMEM®). RESULTS: A two-compartment model best described the pharmacokinetics of doxapram and keto-doxapram. PNA and GA affected the formation clearance of keto-doxapram (CL(FORMATION KETO-DOXAPRAM)) and clearance of doxapram via other routes (CL(DOXAPRAM OTHER ROUTES)). For a median individual of 0.95 kg, GA 25.6 weeks, and PNA 29 days, CL(FORMATION KETO-DOXAPRAM) was 0.115 L/h (relative standard error (RSE) 12%) and CL(DOXAPRAM OTHER ROUTES) was 0.645 L/h (RSE 9%). Oral bioavailability was estimated at 74% (RSE 10%). CONCLUSIONS: Dosing of doxapram only based on bodyweight results in the highest exposure in preterm infants with the lowest PNA and GA. Therefore, dosing may need to be adjusted for GA and PNA to minimize the risk of accumulation and adverse events. For switching to oral therapy, a 33% dose increase is required to maintain exposure. IMPACT: Current dosing regimens of doxapram in preterm infants only based on bodyweight result in the highest exposure in infants with the lowest PNA and GA. Dosing of doxapram may need to be adjusted for GA and PNA to minimize the risk of accumulation and adverse events. Describing the pharmacokinetics of doxapram and its active metabolite keto-doxapram following intravenous and gastroenteral administration enables to include drug exposure to the evaluation of treatment of AOP. The oral bioavailability of doxapram in preterm neonates is 74%, requiring a 33% hig
- Published
- 2021
21. Chloroquine for treatment of COVID-19 results in subtherapeutic exposure and prolonged QTc intervals
- Author
-
Brüggemann, R.J., primary, Moes, D.J.A.R., additional, van Rhee, K.P., additional, van 't Veer, N.E., additional, Koch, B.C.P., additional, van Rossum, M., additional, Windsant - van den Tweel, A. Vermeulen, additional, Reijers, M.H.E., additional, van Kimmenade, R.R.J., additional, Rahamat-Langedoen, J.C., additional, Rettig, T.C.D., additional, van Raalte, R., additional, van Paassen, J., additional, Polderman, F.N., additional, van der Linden, P.D., additional, Frenzel, T., additional, de Mast, Q., additional, Burger, D.M., additional, Schouten, J., additional, van de Veerdonk, F.L., additional, Pickkers, P., additional, and ter Heine, R., additional
- Published
- 2021
- Full Text
- View/download PDF
22. The bioavailability and maturing clearance of doxapram in preterm infants
- Author
-
Flint, R.B., Simons, S.H.P., Andriessen, P., Liem, K.D., Degraeuwe, P.L.J., Reiss, I.K.M., Ter Heine, R., Engbers, A.G.J., Koch, B.C.P., Groot, R. de, Burger, D.M., Knibbe, C.A..J., Völler, S., and DINO Research Group
- Abstract
Background Doxapram is used for the treatment of apnea of prematurity in dosing regimens only based on bodyweight, as pharmacokinetic data are limited. This study describes the pharmacokinetics of doxapram and keto-doxapram in preterm infants. Methods Data (302 samples) from 75 neonates were included with a median (range) gestational age (GA) 25.9 (23.9-29.4) weeks, bodyweight 0.95 (0.48-1.61) kg, and postnatal age (PNA) 17 (1-52) days at the start of continuous treatment. A population pharmacokinetic model was developed using non-linear mixed-effects modelling (NONMEM (R)). Results A two-compartment model best described the pharmacokinetics of doxapram and keto-doxapram. PNA and GA affected the formation clearance of keto-doxapram (CLFORMATION KETO-DOXAPRAM) and clearance of doxapram via other routes (CLDOXAPRAM OTHER ROUTES). For a median individual of 0.95 kg, GA 25.6 weeks, and PNA 29 days, CL(FORMATION KETO-DOXAPRAM)was 0.115 L/h (relative standard error (RSE) 12%) and CL(DOXAPRAM OTHER ROUTES)was 0.645 L/h (RSE 9%). Oral bioavailability was estimated at 74% (RSE 10%). Conclusions Dosing of doxapram only based on bodyweight results in the highest exposure in preterm infants with the lowest PNA and GA. Therefore, dosing may need to be adjusted for GA and PNA to minimize the risk of accumulation and adverse events. For switching to oral therapy, a 33% dose increase is required to maintain exposure. ImpactCurrent dosing regimens of doxapram in preterm infants only based on bodyweight result in the highest exposure in infants with the lowest PNA and GA. Dosing of doxapram may need to be adjusted for GA and PNA to minimize the risk of accumulation and adverse events. Describing the pharmacokinetics of doxapram and its active metabolite keto-doxapram following intravenous and gastroenteral administration enables to include drug exposure to the evaluation of treatment of AOP. The oral bioavailability of doxapram in preterm neonates is 74%, requiring a 33% higher dose via oral than intravenous administration to maintain exposure.
- Published
- 2020
23. Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents
- Author
-
Zeitlinger, M., Koch, B.C.P., Bruggemann, R.J.M., Cock, P. De, Felton, T., Hites, M., Le, J., Luque, S., MacGowan, A.P., Marriott, D.J.E., Muller, A.E., Nadrah, K., Paterson, D.L., Standing, J.F., Telles, J.P., Wölfl-Duchek, M., Thy, M., Roberts, J.A., Zeitlinger, M., Koch, B.C.P., Bruggemann, R.J.M., Cock, P. De, Felton, T., Hites, M., Le, J., Luque, S., MacGowan, A.P., Marriott, D.J.E., Muller, A.E., Nadrah, K., Paterson, D.L., Standing, J.F., Telles, J.P., Wölfl-Duchek, M., Thy, M., and Roberts, J.A.
- Abstract
Contains fulltext : 229191.pdf (Publisher’s version ) (Open Access), There is an urgent need to identify optimal antiviral therapies for COVID-19 caused by SARS-CoV-2. We have conducted a rapid and comprehensive review of relevant pharmacological evidence, focusing on (1) the pharmacokinetics (PK) of potential antiviral therapies; (2) coronavirus-specific pharmacodynamics (PD); (3) PK and PD interactions between proposed combination therapies; (4) pharmacology of major supportive therapies; and (5) anticipated drug-drug interactions (DDIs). We found promising in vitro evidence for remdesivir, (hydroxy)chloroquine and favipiravir against SARS-CoV-2; potential clinical benefit in SARS-CoV-2 with remdesivir, the combination of lopinavir/ritonavir (LPV/r) plus ribavirin; and strong evidence for LPV/r plus ribavirin against Middle East Respiratory Syndrome (MERS) for post-exposure prophylaxis in healthcare workers. Despite these emerging data, robust controlled clinical trials assessing patient-centred outcomes remain imperative and clinical data have already reduced expectations with regard to some drugs. Any therapy should be used with caution in the light of potential drug interactions and the uncertainty of optimal doses for treating mild versus serious infections.
- Published
- 2020
24. Monitoring the tacrolimus concentration in peripheral blood mononuclear cells of kidney transplant recipients
- Author
-
Francke, M.I. (Marith I.), Hesselink, D.A. (Dennis), Li, Y. (Yi), Koch, B.C.P. (Birgit), Wit, L.E.A. (Elly) de, Schaik, R.H.N. (Ron) van, Yang, L. (Lin), Baan, C.C. (Carla), Gelder, T. (Teun) van, Winter, B.C.M. (Brenda) de, Francke, M.I. (Marith I.), Hesselink, D.A. (Dennis), Li, Y. (Yi), Koch, B.C.P. (Birgit), Wit, L.E.A. (Elly) de, Schaik, R.H.N. (Ron) van, Yang, L. (Lin), Baan, C.C. (Carla), Gelder, T. (Teun) van, and Winter, B.C.M. (Brenda) de
- Abstract
Aims: Tacrolimus is a critical dose drug and to avoid under- and overexposure, therapeutic drug monitoring is standard practice. However, rejection and drug-related toxicity occur despite whole-blood tacrolimus pre-dose concentrations ([Tac]blood) being on target. Monitoring tacrolimus concentrations at the target site (within peripheral blood mononuclear cells; [Tac]cells) may better correlate with drug-efficacy. The aim of this study was to (1) investigate the relationship between [Tac]blood and [Tac]cells, (2) identify factors affecting the tacrolimus distribution in cells and whole-blood, and (3) study the relationship between [Tac]cells and clinical outcomes after kidney transplantation. Methods: A total of 175 renal transplant recipients were prospectively followed. [Tac]blood and [Tac]cells were determined at Months 3, 6 and 12 post-transplantation. Patients were genotyped for ABCB1 1199G>A and 3435C>T, CYP3A4 15389C>T, and CYP3A5 6986G>A. Data on rejection and tacrolimus-related nephrotoxicity and post-transplant diabetes mellitus were collected. Results: Correlations between [Tac]blood and [Tac]cells were moderate to poor (Spearman's r = 0.31; r = 0.41; r = 0.61 at Months 3, 6 and 12, respectively). The [Tac]cells/[Tac]blood ratio was stable over time in most patients (median intra-patient variability 39.0%; range 3.5%–173.2%). Age, albumin and haematocrit correlated with the [Tac]cells/[Tac]blood ratio. CYP3A5 and CYP3A4 genotype combined affected both dose-corrected [Tac]blood and [Tac]cells. ABCB1 was not significantly related to tacrolimus distribution. Neither [Tac]blood nor [Tac]cells correlated with clinical outcomes. Conclusions: The correlation between [Tac]blood and [Tac]cells is poor. Age, albumin and haematocrit correlate with the [Tac]cells/[Tac]blood ratio, whereas genetic variation in ABCB1, CYP3A4 and CYP3A5 do not. Neither [Tac]blood nor [Tac]cells correlated with clinical outcomes.
- Published
- 2020
- Full Text
- View/download PDF
25. Pharmacogenomic response of low dose haloperidol in critically ill adults with delirium
- Author
-
Trogrlić, Z. (Zoran), Jagt, M. (Mathieu) van der, Osse, R.J. (Robert Jan), Devlin, J.W. (John W.), Nieboer, D. (Daan), Koch, B.C.P. (Birgit), Schaik, R.H.N. (Ron) van, Hunfeld, N.G.M. (Nicole), Trogrlić, Z. (Zoran), Jagt, M. (Mathieu) van der, Osse, R.J. (Robert Jan), Devlin, J.W. (John W.), Nieboer, D. (Daan), Koch, B.C.P. (Birgit), Schaik, R.H.N. (Ron) van, and Hunfeld, N.G.M. (Nicole)
- Abstract
Purpose: To characterize the pharmacogenomic response of low-dose haloperidol for delirium treatment in critically ill adults. Materials and methods: Single-center, pilot study of a convenience sample of ICU adults with delirium treated with low-dose IV haloperidol. Patients were evaluated for delirium with the ICDSC every 8 h. Serum haloperidol concentrations were collected on ICU days 2–6, CYP2D6 and CYP3A4 genotypes were characterized and patients were categorized as extensive (EM), intermediate (IM) or poor metabolizers (PM). Results: The 22 patients (median age 67 [IQR 48,77] years; median APACHE III 81[IQR 54,181]; CYP2D6 [EM = 12, IM = 7, PM = 3], CYP3A [EM = 18, IM = 4]) received a median [IQR] daily haloperidol dose of 3.0 [2.4, 4.5] mg. After adjusting for age, SOFA, and ICU day, neither an association between CYP2D6 (IM p = .67/PM p = .25) or CYP3A4 (IM p = .44) metabolizer status and serum haloperidol concentrations was found. After adjusting for age, SOFA, and ICU day, neither an association between daily haloperidol dose (p = .77) or ICDSC score (p = .13) and serum haloperidol concentrations was found. No patient experienced QTc interval prolongation (≥500 ms). Conclusions: This pilot study, the first to evaluate the pharmacogenomic response of low-dose haloperidol when used to treat delirium in the ICU, suggests CYP2D6/CYP3A4 metabolizer status does not affect the serum haloperidol concentrations.
- Published
- 2020
- Full Text
- View/download PDF
26. Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents
- Author
-
Zeitlinger, M. (Markus), Koch, B.C.P. (Birgit), Brüggemann, M. (Monika), De Cock, P. (Pieter), Felton, T. (Timothy), Hites, M. (Maya), Le, J. (Jennifer), Luque, S. (Sonia), MacGowan, A.P. (Alasdair P.), Marriott, D.J.E. (Deborah J. E.), Muller, A.E. (Anouk), Nadrah, K. (Kristina), Paterson, D.L. (David L), Standing, J.F. (Joseph), Telles, J.P. (João P.), Wölfl-Duchek, M. (Michael), Thy, M. (Michael), Roberts, J.A. (Jason A.), Zeitlinger, M. (Markus), Koch, B.C.P. (Birgit), Brüggemann, M. (Monika), De Cock, P. (Pieter), Felton, T. (Timothy), Hites, M. (Maya), Le, J. (Jennifer), Luque, S. (Sonia), MacGowan, A.P. (Alasdair P.), Marriott, D.J.E. (Deborah J. E.), Muller, A.E. (Anouk), Nadrah, K. (Kristina), Paterson, D.L. (David L), Standing, J.F. (Joseph), Telles, J.P. (João P.), Wölfl-Duchek, M. (Michael), Thy, M. (Michael), and Roberts, J.A. (Jason A.)
- Abstract
There is an urgent need to identify optimal antiviral therapies for COVID-19 caused by SARS-CoV-2. We have conducted a rapid and comprehensive review of relevant pharmacological evidence, focusing on (1) the pharmacokinetics (PK) of potential antiviral therapies; (2) coronavirus-specific pharmacodynamics (PD); (3) PK and PD interactions between proposed combination therapies; (4) pharmacology of major supportive therapies; and (5) anticipated drug–drug interactions (DDIs). We found promising in vitro evidence for remdesivir, (hydroxy)chloroquine and favipiravir against SARS-CoV-2; potential clinical benefit in SARS-CoV-2 with remdesivir, the combination of lopinavir/ritonavir (LPV/r) plus ribavirin; and strong evidence for LPV/r plus ribavirin against Middle East Respiratory Syndrome (MERS) for post-exposure prophylaxis in healthcare workers. Despite these emerging data, robust controlled clinical trials assessing patient-centred outcomes remain imperative and clinical data have already reduced expectations with regard to some drugs. Any therapy should be used with caution in the light of potential drug interactions and the uncertainty of optimal doses for treating mild versus serious infections.
- Published
- 2020
- Full Text
- View/download PDF
27. Clinical Validation of a Dried Blood Spot Assay for 8 Antihypertensive Drugs and 4 Active Metabolites
- Author
-
Peeters, L.E.J. (Laura), Feyz, L. (Lida), Hameli, E. (Edon), Zwart, T. (Tom), Bahmany, S. (Soma), Daemen, J. (Joost), Gelder, T. (Teun) van, Versmissen, J. (Jorie), Koch, B.C.P. (Birgit), Peeters, L.E.J. (Laura), Feyz, L. (Lida), Hameli, E. (Edon), Zwart, T. (Tom), Bahmany, S. (Soma), Daemen, J. (Joost), Gelder, T. (Teun) van, Versmissen, J. (Jorie), and Koch, B.C.P. (Birgit)
- Abstract
BACKGROUND: Drug nonadherence is one of the major challenges faced by resistant hypertension patients, and identification of this problem is needed for optimizing pharmacotherapy. Dried blood spot (DBS) sampling is a minimally invasive method designed to detect and determine the degree of nonadherence. In this study, a DBS method for qualifying 8 antihypertensive drugs (AHDs) and 4 active metabolites was developed and validated using ultra high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS). METHOD: The DBS assay was validated analytically and clinically, in accordance with FDA requirements. Analytical validation was accomplished using UHPLC-MS/MS. For clinical validation, paired peak and trough levels of DBS and plasma samples were simultaneously collected and comparatively analyzed using Deming regression and Bland-Altman analyses. All concentrations below the set lower limit were excluded. Deming regression analysis was used to predict comparison bias between the collected plasma and DBS samples, with DBS concentrations corrected accordingly. RESULTS: The UHPLC-MS/MS method for simultaneously measuring 8 AHDs and their metabolites in DBS, was successfully validated. With Deming regression no bias was observed in N = 1; constant bias was seen in N = 6 and proportional bias in N = 11 of the AHDs and metabolites. After correction for bias, only one metabolite (canrenone) met the 20% acceptance limit for quantification, after Bland-Altman analyses. In addition, amlodipine, valsartan, and [enalaprilate] met the 25% acceptance limit. CONCLUSIONS: A novel DBS assay for simultaneously qualifying and quantifying 8 AHDs and their metabolites, has been successfully developed and validated. The DBS assay is therefore a suitable method to detect drug nonadherence. However, with the exception of canrenone, the interchangeable use of plasma and DBS sam
- Published
- 2020
- Full Text
- View/download PDF
28. Finger-Prick Blood Sampling for Therapeutic Drug Monitoring: Be Aware of Skin Contamination by Nebulized Drugs
- Author
-
Winter, B.C.M. (Brenda) de, Hoog, M. (Matthijs) de, Vet, N.J. (Nienke), Dunk-Craaijo, J.H. (Joke H.), Koch, B.C.P. (Birgit), Wildt, S.N. (Saskia) de, Winter, B.C.M. (Brenda) de, Hoog, M. (Matthijs) de, Vet, N.J. (Nienke), Dunk-Craaijo, J.H. (Joke H.), Koch, B.C.P. (Birgit), and Wildt, S.N. (Saskia) de
- Published
- 2020
- Full Text
- View/download PDF
29. Feasibility of Dried Blood Spots in Children with Behavioral Problems
- Author
-
Kloosterboer, S.M. (Sanne), van Eijk, E. (Estelle), Dijk, M. (Monique) van, Dieleman, G.C. (Gwen), Hillegers, M.H.J. (Manon), van Gelder, T. (Teun), Koch, B.C.P. (Birgit), Dierckx, B. (Bram), Kloosterboer, S.M. (Sanne), van Eijk, E. (Estelle), Dijk, M. (Monique) van, Dieleman, G.C. (Gwen), Hillegers, M.H.J. (Manon), van Gelder, T. (Teun), Koch, B.C.P. (Birgit), and Dierckx, B. (Bram)
- Abstract
BACKGROUND: Minimally invasive sampling methods are important to facilitate therapeutic drug monitoring and pharmacokinetic research in children with behavioral problems. This study assessed the feasibility and pain of dried blood spot (DBS) sampling in this population. METHODS: Repeated DBS sampling was performed in children with autism spectrum disorder (ASD) and severe behavioral problems using antipsychotic drugs, aged between 6 and 18 years. The child, guardian, and DBS performer assessed pain using the numeric rating scale (NRS-11) or 5-face Faces Pain Scale. The influence of age, sex, and the fingerprick performer on the child's pain intensity was analyzed using linear mixed models. RESULTS: Overall, 247 fingerpricks were performed in 70 children. Seven children refused all DBS sampling. The median (interquartile range) NRS-11 pain scores were 2 (3) rated by children, 3 (2.5) by guardians, and 2 (2) by fingerprick performers. The child's age and sex, and fingerprick performer had no significant influence on pain intensity. CONCLUSIONS: DBS sampling could be performed in most children with ASD and severe behavioral problems. However, 1 in 5 children refused one or more DBS fingerpricks owing to distress. Most expressed minimal pain (NRS < 4). Repeated sampling with DBS is feasible in children with ASD and severe behavioral problems.
- Published
- 2020
- Full Text
- View/download PDF
30. Pregnancy related pharmacokinetics and antimicrobial prophylaxis during fetal surgery, cefazolin and clindamycin as examples
- Author
-
Allegaert, K.M. (Karel), Muller, A.E. (Anouk), Russo, F. (Francesca), Schoenmakers, S. (Sam), Deprest, J., Koch, B.C.P. (Birgit), Allegaert, K.M. (Karel), Muller, A.E. (Anouk), Russo, F. (Francesca), Schoenmakers, S. (Sam), Deprest, J., and Koch, B.C.P. (Birgit)
- Abstract
Antimicrobial prophylaxis during surgery aims to prevent post-operative site infections. For fetal surgery, this includes the fetal and amniotic compartments. Both are deep compartments as drug equilibrium with maternal blood is achieved relatively late. Despite prophylaxis, chorio-amnionitis or endometritis following ex utero intrapartum treatment or fetoscopy occur in 4.13% and 1.45% respectively of the interventions. This review summarizes the observations on two commonly administered antimicrobials (cefazolin, clindamycin) for surgical prophylaxis during pregnancy, with emphasis on the deep compartments. For both compounds, antimicrobial exposure is on target when we consider the maternal and fetal plasma compartment. In contrast, amniotic fluid concentrations-time profiles display a delayed and much more blunted pattern, behaving as deep compartment. For cefazolin, there are data that document further dilution in the setting of polyhydramnios. Along this deep compartment concept, there is some accumulation during repeated administration, modeled for cefazolin and observed for clindamycin. The relative underexposure to antimicrobials in amniotic fluid may be reflected in the pattern of maternal-fetal complications after fetal surgery, and suggest that antimicrobial prophylaxis practices for fetal surgery should be reconsidered. Further studies should be designed by a multidisciplinary team (fetal surgeons, clinical pharmacologists and microbiologists) to facilitate efficient evaluation of antimicrobial prophylaxis.
- Published
- 2020
- Full Text
- View/download PDF
31. Sequestration of Voriconazole and Vancomycin Into Contemporary Extracorporeal Membrane Oxygenation Circuits: Anin vitroStudy
- Author
-
Raffaeli, G., Cavallaro, G, Allegaert, K.M. (Karel), Koch, B.C.P., Mosca, F., Tibboel, D. (Dick), Wildschut, E.D. (Enno), Raffaeli, G., Cavallaro, G, Allegaert, K.M. (Karel), Koch, B.C.P., Mosca, F., Tibboel, D. (Dick), and Wildschut, E.D. (Enno)
- Abstract
Background: Bacterial and fungal infections are common and often contribute to death in patients undergoing extracorporeal membrane oxygenation (ECMO). Drug disposition is altered during ECMO, and adsorption in the circuit is an established causative factor. Vancomycin and voriconazole are widely used, despite the lack of evidence-based prescription guidelines. Objective: The objective of this study was to determine the extraction of voriconazole and vancomycin by the Xenios/Novalung ECMO circuits. Methods: We have set up nine closed-loop ECMO circuits, consisting of four different iLAActivve® kits for neonatal, pediatric, and adult support: three iLA-ActivveMiniLung® petite kits, two iLA-ActivveMiniLung® kits, two iLA-ActivveiLA® kits, and two iLA-Activve X-lung® kits. The circuits were primed with whole blood and maintained at physiologic conditions for 24 h. Voriconazole and vancomycin were injected as a single-bolus age-related dose into the circuits. Pre-membrane (P2) blood samples were obtained at baseline and after drug injection at 2, 10, 30, 180, 360 min, and 24 h. A control sample at 2 min was collected for spontaneous drug degradation testing at 24 h. Results: Seventy-two samples were analyzed in triplicate. The mean percentage of drug recovery at 24 h was 20% for voriconazole and 62% for vancomycin. Conclusions: The extraction of voriconazole and vancomycin by contemporary ECMO circuits is clinically relevant across all age-related circuit sizes and may result in reduced drug exposure in vivo.
- Published
- 2020
- Full Text
- View/download PDF
32. Failure of target attainment of beta-lactam antibiotics in critically ill patients and associated risk factors: a two-center prospective study (EXPAT)
- Author
-
Abdulla, A., Dijkstra, A., Hunfeld, N.G.M., Endeman, H., Bahmany, S., Ewoldt, T.M.J., Muller, A.E., Gelder, T. (Teun) van, Gommers, D.A.M.P.J. (Diederik), Koch, B.C.P., Abdulla, A., Dijkstra, A., Hunfeld, N.G.M., Endeman, H., Bahmany, S., Ewoldt, T.M.J., Muller, A.E., Gelder, T. (Teun) van, Gommers, D.A.M.P.J. (Diederik), and Koch, B.C.P.
- Abstract
Background: Early and appropriate antibiotic dosing is associated with improved clinical outcomes in critically ill patients, yet target attainment remains a challenge. Traditional antibiotic dosing is not suitable in critically ill patients, since these patients undergo physiological alterations that strongly affect antibiotic exposure. For betalactam antibiotics, the unbound plasma concentrations above at least one to four times the minimal inhibitory concentration (MIC) for 100% of the dosing interval (100%ƒT>1–4×MIC) have been proposed as pharmacodynamic targets (PDTs) to maximize bacteriological and clinical responses. The objectives of this study are to describe the PDT attainment in critically ill patients and to identify risk factors for target non-attainment. Methods: This prospective observational study was performed in two ICUs in the Netherlands. We enrolled adult patients treated with the following beta-lactam antibiotics: amoxicillin (with or without clavulanic acid), cefotaxime, ceftazidime, ceftriaxone, cefuroxime, and meropenem. Based on five samples within a dosing interval at day 2 of therapy, the time unbound concentrations above the epidemiological cut-off (ƒT > MICECOFF and ƒT > 4×MICECOFF) were determined. Secondary endpoints were estimated multivariate binomial and binary logistic regression models, for examining the association of PDT attainment with patient characteristics and clinical outcomes. Results: A total of 147 patients were included, of whom 63.3% achieved PDT of 100%ƒT > MICECOFF and 36.7% achieved 100%ƒT > 4×MICECOFF. Regression analysis identified male gender, estimated glomerular filtration rate (eGFR) ≥ 90 mL/min/1.73 m2 , and high body mass index (BMI) as risk factors for target non-attainment. Use of continuous renal replacement therapy (CRRT) and high serum urea significantly increased the probability of target attainment. In addition, we found a significant association between the 100%ƒT > MICECOFF target attainment and IC
- Published
- 2020
- Full Text
- View/download PDF
33. Psychotropic drug concentrations and clinical outcomes in children and adolescents: a systematic review
- Author
-
Kloosterboer, S.M. (Sanne), Vierhout, D. (Denise), Stojanova, J. (Jana), Egberts, K.M. (Karin M.), Gerlach, M. (Manfred), Dieleman, G.C. (Gwen), Hillegers, M.H.J. (Manon), Passe, K.M. (Kimberly M.), Gelder, T. (Teun) van, Dierckx, B. (Bram), Koch, B.C.P. (Birgit), Kloosterboer, S.M. (Sanne), Vierhout, D. (Denise), Stojanova, J. (Jana), Egberts, K.M. (Karin M.), Gerlach, M. (Manfred), Dieleman, G.C. (Gwen), Hillegers, M.H.J. (Manon), Passe, K.M. (Kimberly M.), Gelder, T. (Teun) van, Dierckx, B. (Bram), and Koch, B.C.P. (Birgit)
- Abstract
Introduction: The use of psychotropic drugs in children and adolescents is widespread but associated with suboptimal treatment effects. Therapeutic drug monitoring (TDM) can improve safety of psychotropic drugs in children and adolescents but is not routinely performed. A major reason is that the relationship between drug concentrations and effects is not well known. Areas covered: This systematic review evaluated studies assessing the relationship between psychotropic drug concentrations and clinical outcomes in children and adolescents, including antipsychotics, psychostimulants, alpha-agonists, antidepressants, and mood-stabilizers. PRISMA guidelines were used and a quality assessment of the retrieved studies was performed. Sixty-seven eligible studies involving 24 psychotropic drugs were identified from 9,298 records. The findings were generally heterogeneous and the majority of all retrieved studies were not of sufficient quality. For 11 psychotropic drugs, a relationship between drug concentrations and side-effects and/or effectiveness was evidenced in reasonably reported and executed studies, but these findings were barely replicated. Expert opinion: In order to better support routine TDM in child- and adolescent psychiatry, future work must improve in aspects of study design, execution and reporting to demonstrate drug concentration-effect relationships. The quality criteria proposed in this work can guide future TDM research. Systematic review protocol and registration PROSPERO CRD42018084159.
- Published
- 2020
- Full Text
- View/download PDF
34. Risperidone plasma concentrations are associated with side effects and effectiveness in children and adolescents with autism spectrum disorder
- Author
-
Kloosterboer, S.M. (Sanne), Winter, B.C.M. (Brenda) de, Reichart, C.G. (Catrien), Kouijzer, M.E.J. (Mirjam E.J.), de Kroon, M.M.J. (Matthias M.J.), Daalen, E. (Emma) van, Ester, W.A. (Wietske), Rieken, R. (Rob), Dieleman, G.C. (Gwen), van Altena, D. (Daphne), Bartelds, B. (Beatrijs), Schaik, R.H.N. (Ron) van, Nasserinejad, K. (Kazem), Hillegers, M.H.J. (Manon), Gelder, T. (Teun) van, Dierckx, B. (Bram), Koch, B.C.P. (Birgit), Kloosterboer, S.M. (Sanne), Winter, B.C.M. (Brenda) de, Reichart, C.G. (Catrien), Kouijzer, M.E.J. (Mirjam E.J.), de Kroon, M.M.J. (Matthias M.J.), Daalen, E. (Emma) van, Ester, W.A. (Wietske), Rieken, R. (Rob), Dieleman, G.C. (Gwen), van Altena, D. (Daphne), Bartelds, B. (Beatrijs), Schaik, R.H.N. (Ron) van, Nasserinejad, K. (Kazem), Hillegers, M.H.J. (Manon), Gelder, T. (Teun) van, Dierckx, B. (Bram), and Koch, B.C.P. (Birgit)
- Abstract
Aim: Risperidone is the most commonly prescribed antipsychotic drug to children and adolescents worldwide, but it is associated with serious side effects, including weight gain. This study assessed the relationship of risperidone and 9-hydroxyrisperidone trough concentrations, maximum concentrations and 24-hour area under the curves (AUCs) with body mass index (BMI) z-scores in children and adolescents with autism spectrum disorder (ASD) and behavioural problems. Secondary outcomes were metabolic, endocrine, extrapyramidal and cardiac side effects and effectiveness. Methods: Forty-two children and adolescents (32 males) aged 6-18 years were included in a 24-week prospective observational trial. Drug plasma concentrations, side effects and effectiveness were measured at several time points during follow-up. Relevant pharmacokinetic covariates, including medication adherence and CYP2D6, CYP3A4, CYP3A5 and P-glycoprotein (ABCB1) genotypes, were measured. Nonlinear mixed-effects modelling (NONMEM®) was used for a population pharmacokinetic analysis with 205 risperidone and 205 9-hydroxyrisperidone concentrations. Subsequently, model-based trough concentrations, maximum concentrations and 24-hour AUCs were analysed to predict outcomes using generalized and linear mixed-effects models. Results: A risperidone two-compartment model combined with a 9-hydroxyrisperidone one-compartment model best described the measured concentrations. Of all the pharmacokinetic parameters, higher risperidone sum trough concentrations best predicted higher BMI z-scores during follow-up (P <.001). Higher sum trough concentrations also predicted more sedation (P <.05), higher prolactin levels (P <.001) and more effectiveness measured with Aberrant Behavior Checklist irritability score (P <.01). Conclusion: Our results indicate a therapeutic window exists, which suggests that therapeutic drug monitoring of risperidone might increase safety and effectiveness in children and adolescents with ASD an
- Published
- 2020
- Full Text
- View/download PDF
35. The effectiveness of nitrofurantoin, fosfomycin and trimethoprim for the treatment of cystitis in relation to renal function
- Author
-
ten Doesschate, T. (T.), van Haren, E. (E.), Wijma, R.A. (Rixt), Koch, B.C.P. (Birgit), Bonten, M., van Werkhoven, C.H. (C. H.), ten Doesschate, T. (T.), van Haren, E. (E.), Wijma, R.A. (Rixt), Koch, B.C.P. (Birgit), Bonten, M., and van Werkhoven, C.H. (C. H.)
- Abstract
Objectives: We evaluated the effect of renal function on clinical failure rates of nitrofurantoin, fosfomycin and trimethoprim for the treatment of cystitis in primary care. Methods: Data were retrospectively obtained from 78 Dutch general practitioner (GP) practices between 2013 and 2019. Eligible episodes in patients (>11 years) were those requiring 5 days of nitrofurantoin (NF5), single-dose fosfomycin–trometamol (FT1), 3 days of trimethoprim (TMP3) for uncomplicated cystitis, or 7 days of nitrofurantoin (NF7) or trimethoprim (TMP7) for complicated cystitis. Clinical failure was defined as second antibiotic prescription for cystitis or pyelonephritis within 28 days post-prescription. Mixed effects regression analysis was used, with patient and GP practice as random effects and demography, comorbidity, and cystitis history as fixed effects. Results: Adjusted odds ratios (aORs) for clinical failure per 10mL/min decrease in estimated glomerular filtration rate (eGFR) were 1.05 (95% CI: 1.01–1.09) for NF5 (n = 24,591), 0.96 (95% CI: 0.92–1.01) for FT1 (n = 5359), 0.98 (95% CI: 0.89–1.08) for TMP3 (n = 1064), 1.05 (95% CI: 1.02–1.09) for NF7 (n = 10,628) and 1.02 (95% CI: 0.93–1.14) for TMP7 (n = 831). In uncomplicated cystitis and eGFR ≥60 mL/min, clinical failures occurred in 14.6% (1895/12 980) of NF5-treated, 20.7% (266/1283) of FT1-treated (aOR versus NF5 1.37, 95% CI 1.18–1.59) and 20.8% (66/318) of TMP3-treated patients (aOR 1.42, 95% CI 1.07–1.87 versus NF5). In uncomplicated cystitis and eGFR <60 mL/min, FT1 resulted in 16.0% (39/244) and NF5 in 23.3% clinical failures (110/472), aOR: 0.61, 95% CI: 0.39–0.95). Conclusions: In eGFR ≥60 mL/min treatment with fosfomycin or trimethoprim for uncomplicated cystitis was associated with more clinical failure than treatment with nitrofurantoin, while in eGFR <60 mL/min nitrofurantoin was associated with more clinical failure than fosfomycin–trometamol. Renal function, if known, should be considered in the clinical dec
- Published
- 2020
- Full Text
- View/download PDF
36. Population pharmacokinetics and target attainment of ciprofloxacin in critically ill patients
- Author
-
Abdulla, A. (Alan), Rogouti, O. (Omar), Hunfeld, N.G.M. (Nicole), Endeman, H. (Henrik), Dijkstra, A. (Annemieke), Gelder, T. (Teun) van, Muller, A.E. (Anouk), Winter, B.C.M. (Brenda) de, Koch, B.C.P. (Birgit), Abdulla, A. (Alan), Rogouti, O. (Omar), Hunfeld, N.G.M. (Nicole), Endeman, H. (Henrik), Dijkstra, A. (Annemieke), Gelder, T. (Teun) van, Muller, A.E. (Anouk), Winter, B.C.M. (Brenda) de, and Koch, B.C.P. (Birgit)
- Abstract
Purpose: To develop and validate a population pharmacokinetic model of ciprofloxacin intravenously in critically ill patients, and determine target attainment to provide guidance for more effective regimens. Methods: Non-linear mixed-effects modelling was used for the model development and covariate analysis. Target attainment of an ƒAUC0–24/MIC ≥ 100 for different MICs was calculated for standard dosing regimens. Monte Carlo simulations were performed to define the probability of target attainment (PTA) of several dosing regimens. Results: A total of 204 blood samples were collected from 42 ICU patients treated with ciprofloxacin 400–1200 mg/day, with median values for age of 66 years, APACHE II score of 22, BMI of 26 kg/m2, and eGFR of 58.5 mL/min/1.73 m2. The median ƒAUC0–24 and ƒCmax were 29.9 mg•h/L and 3.1 mg/L, respectively. Ciprofloxacin pharmacokinetics were best described by a two-compartment model. We did not find any significant covariate to add to the structural model. The proportion of patients achieving the target ƒAUC0–24/MIC ≥ 100 were 61.9% and 16.7% with MICs of 0.25 and 0.5 mg/L, respectively. Results of the PTA simulations suggest that a dose of ≥ 1200 mg/day is needed to achieve sufficient ƒAUC0–24/MIC ratios. Conclusions: The model described the pharmacokinetics of ciprofloxacin in ICU patients adequately. No significant covariates were found and high inter-individual variability of ciprofloxacin pharmacokinetics in ICU patients was observed. The poor target attainment supports the use of higher doses such as 1200 mg/day in critically ill patients, while the variability of inter-individual pharmacokinetics parameters emphasizes the need for therapeutic drug monitoring to ensure optimal exposure.
- Published
- 2020
- Full Text
- View/download PDF
37. Pipamperone Population Pharmacokinetics Related to Effectiveness and Side Effects in Children and Adolescents
- Author
-
Kloosterboer, S.M. (Sanne), Egberts, K.M. (Karin M.), Winter, B.C.M. (Brenda) de, Gelder, T. (Teun) van, Gerlach, M. (Manfred), Hillegers, M.H.J. (Manon), Dieleman, G.C. (Gwen), Bahmany, S. (Soma), Reichart, C.G. (Catrien), van Daalen, E. (Emma), Kouijzer, M.E.J. (Mirjam E. J.), Dierckx, B. (Bram), Koch, B.C.P. (Birgit), Kloosterboer, S.M. (Sanne), Egberts, K.M. (Karin M.), Winter, B.C.M. (Brenda) de, Gelder, T. (Teun) van, Gerlach, M. (Manfred), Hillegers, M.H.J. (Manon), Dieleman, G.C. (Gwen), Bahmany, S. (Soma), Reichart, C.G. (Catrien), van Daalen, E. (Emma), Kouijzer, M.E.J. (Mirjam E. J.), Dierckx, B. (Bram), and Koch, B.C.P. (Birgit)
- Abstract
Background: Pipamperone is a frequently prescribed antipsychotic in children and adolescents in the Netherlands, Belgium, and Germany. However, pediatric pharmacokinetics and the relationship with side effects and efficacy are unknown. Currently, divergent pediatric dosing recommendations exist. Objectives: The objective of this study was to describe the population pharmacokinetics of pipamperone in children and adolescents; to correlate measured and predicted pipamperone trough concentrations and predicted 24-h area under the curves with effectiveness, extrapyramidal symptoms, and sedation; and to propose dose recommendations based on simulations. Methods: Pipamperone concentrations were collected from Dutch pediatric patients in a prospective naturalistic trial (n = 8), and German pediatric patients in a therapeutic drug monitoring service (n = 22). A total of 70 pipamperone concentrations were used to develop a population pharmacokinetic model with non-linear mixed-effects modeling (NONMEM®). Additionally, an additional random sample of 21 German patients with 33 pipamperone concentrations from the same therapeutic drug monitoring service was used for external validation. Pharmacokinetic parameters were related to clinical improvement, sedation, and extrapyramidal symptoms. Simulations were performed to determine optimal dosages. Results: In a one-compartment model, the apparent volume of distribution was 416 L/70 kg and the apparent clearance was 22.1 L/h/70 kg. Allometric scaling was used to correct for differences in bodyweight. The model was successfully externally validated. The median [25th–75th percentile] measured pipamperone trough concentrations were numerically higher in responders (98.0 µg/L [56.0–180.5 µg/L]) than in non-responders (58.0 µg/L [14.9–105.5 µg/L]), although non-significant (p = 0.14). A twice-daily 0.6-mg/kg dosage was better than a fixed dosage to attain the concentration range observed in responders. Conclusions: Our findings suggest
- Published
- 2020
- Full Text
- View/download PDF
38. Change in Lifestyle Behaviors After Preconception Care: A Prospective Cohort Study
- Author
-
Sijpkens, M.K. (Meertien), van Voors, S.F. (Sabine F.), Rosman, A.N. (Ageeth), Jong-Potjer, L.C. (L.) de, Denktaş, S. (Semiha), Koch, B.C.P. (Birgit), Bertens, L.C.M. (Loes C.M.), Steegers, E.A.P. (Eric), Sijpkens, M.K. (Meertien), van Voors, S.F. (Sabine F.), Rosman, A.N. (Ageeth), Jong-Potjer, L.C. (L.) de, Denktaş, S. (Semiha), Koch, B.C.P. (Birgit), Bertens, L.C.M. (Loes C.M.), and Steegers, E.A.P. (Eric)
- Abstract
Purpose: To evaluate the effects of preconception care (PCC) consultations by change in lifestyle behaviors. Setting and Intervention: Women in deprived neighborhoods of 14 Dutch municipalities were encouraged to visit a general practitioner or midwife for PCC. Sample: The study included women aged 18 to 41 years who had a PCC consultation. Design: In this community-based prospective cohort study, we assessed initiation of folic acid supplementation, cessation of smoking, alcohol consumption, and illicit drug use. Measures: Self-reported and biomarker data on behavioral changes were obtained at baseline and 3 months later. Analysis: The changes in prevalence were assessed with the McNemar test. Results: Of the 259 included participants, paired analyses were available in 177 participants for self-reported outcomes and in 82 for biomarker outcomes. Baseline self-reported prevalence of no folic acid use was 36%, smoking 12%, weekly alcohol use 22%, and binge drinking 17%. Significant changes in prevalence toward better lifestyle during follow-up were seen for folic acid use (both self-reported, P <.001; and biomarker-confirmed, P =.008) and for self-reported binge drinking (P =.007). Conclusion: Our stu
- Published
- 2020
- Full Text
- View/download PDF
39. Population Pharmacokinetics of Imipenem in Critically Ill Patients: A Parametric and Nonparametric Model Converge on CKD-EPI Estimated Glomerular Filtration Rate as an Impactful Covariate
- Author
-
Velde, F. (Femke) de, Winter, B.C.M. (Brenda) de, Neely, M.N. (Michael N.), Yamada, W.M. (Walter M.), Koch, B.C.P. (Birgit C. P.), Harbarth, S. (Stephan), von Dach, E. (Elodie), Gelder, T. (Teun) van, Huttner, A. (Angela), Mouton, J.W. (Johan), Velde, F. (Femke) de, Winter, B.C.M. (Brenda) de, Neely, M.N. (Michael N.), Yamada, W.M. (Walter M.), Koch, B.C.P. (Birgit C. P.), Harbarth, S. (Stephan), von Dach, E. (Elodie), Gelder, T. (Teun) van, Huttner, A. (Angela), and Mouton, J.W. (Johan)
- Abstract
Background: Population pharmacokinetic (popPK) models for antibiotics are used to improve dosing strategies and individualize dosing by therapeutic drug monitoring. Little is known about the differences in results of parametric versus nonparametric popPK models and their potential consequences in clinical practice. We developed both parametric and nonparametric models of imipenem using data from critically ill patients and compared their results. Methods: Twenty-six critically ill patients treated with intravenous imipenem/cilastatin were included in this study. Median estimated glomerular filtration rate (eGFR) measured by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation was 116 mL/min/1.73 m2 (interquartile range 104–124) at inclusion. The usual dosing regimen was 500 mg/500 mg four times daily. On average, five imipenem levels per patient (138 levels in total) were drawn as peak, intermediate, and trough levels. Imipenem concentration-time profiles were analyzed using parametric (NONMEM 7.2) and nonparametric (Pmetrics 1.5.2) popPK software. Results: For both methods, data were best described by a model with two distribution compartments and the CKD-EPI eGFR equation unadjusted for body surface area as a covariate on the elimination rate constant (Ke). The parametric population parameter estimates were Ke 0.637 h−1 (between-subject variability [BSV]: 19.0% coefficient of variation [CV]) and central distribution volume (Vc) 29.6 L (without BSV). The nonparametric values were Ke 0.681 h−1 (34.0% CV) and Vc 31.1 L (42.6% CV). Conclusions: Both models described imipenem popPK well; the parameter estimates were comparable and the included covariate was identical. However, estimated BSV was higher in the nonparametric model. This may have consequences for estimated exposure during dosing simulations and should be further investigated in simulation studies.
- Published
- 2020
- Full Text
- View/download PDF
40. The effect of therapeutic drug monitoring of beta-lactam and fluoroquinolones on clinical outcome in critically ill patients: The DOLPHIN trial protocol of a multi-centre randomised controlled trial
- Author
-
Abdulla, A. (Alan), Ewoldt, T.M.J. (T. M.J.), Hunfeld, N.G.M. (Nicole), Muller, A.E. (Anouk), Rietdijk, W.J.R. (W. J.R.), Polinder, S. (Suzanne), Van Gelder, T. (T.), Endeman, H. (Henrik), Koch, B.C.P. (B. C.P.), Abdulla, A. (Alan), Ewoldt, T.M.J. (T. M.J.), Hunfeld, N.G.M. (Nicole), Muller, A.E. (Anouk), Rietdijk, W.J.R. (W. J.R.), Polinder, S. (Suzanne), Van Gelder, T. (T.), Endeman, H. (Henrik), and Koch, B.C.P. (B. C.P.)
- Abstract
Background: Critically ill patients undergo extensive physiological alterations that will have impact on antibiotic pharmacokinetics. Up to 60% of intensive care unit (ICU) patients meet the pharmacodynamic targets of beta-lactam antibiotics, with only 30% in fluoroquinolones. Not reaching these targets might increase the chance of therapeutic failure, resulting in increased mortality and morbidity, and antibiotic resistance. The DOLPHIN trial was designed to demonstrate the added value of therapeutic drug monitoring (TDM) of beta-lactam and fluoroquinolones in critically ill patients in the ICU. Methods: A multi-centre, randomised controlled trial (RCT) was designed to assess the efficacy and cost-effectiveness of model-based TDM of beta-lactam and fluoroquinolones. Four hundred fifty patients will be included within 24 months after start of inclusion. Eligible patients will be randomly allocated to either study group: the intervention group (active TDM) or the control group (non-TDM). In the intervention group dose adjustment of the study antibiotics (cefotaxime, ceftazidime, ceftriaxone, cefuroxime, amoxicillin, amoxicillin with clavulanic acid, flucloxacillin, piperacillin with tazobactam, meropenem, and ciprofloxacin) on day 1, 3, and 5 is performed based upon TDM with a Bayesian model. The primary outcome will be ICU length of stay. Other outcomes amongst all survival, disease severity, safety, quality of life after ICU discharge, and cost effectiveness will be included. Discussion: No trial has investigated the effect of early TDM of beta-lactam and fluoroquinolones on clinical outcome in critically ill patients. The findings from the DOLPHIN trial will possibly lead to new insights in clinical management of critically ill patients receiving antibiotics. In short, to TDM or not to TDM? Trial registration: EudraCT number: 2017-004677-14. Sponsor protocol name: DOLPHIN. Registered 6 March 2018. Protocol Version 6, Protocol date: 27 November 2019.
- Published
- 2020
- Full Text
- View/download PDF
41. Chloroquine for treatment of COVID-19 - a pig in a poke?
- Author
-
Brüggemann, R.J., primary, Moes, D.J.A.R., additional, van Rhee, K.P., additional, van ’t Veer, N.E., additional, Koch, B.C.P., additional, van Rossum, M., additional, den Tweel, A. Vermeulen Windsant - van, additional, Reijers, M.H.E., additional, van Kimmenade, R.R.J., additional, Rahamat- Langedoen, J.C., additional, Rettig, T.C.D., additional, van Raalte, R., additional, van Paassen, J., additional, Polderman, F.N., additional, van der Linden, P.D., additional, Frenzel, T., additional, de Mast, Q., additional, Burger, D.M., additional, Schouten, J., additional, van de Veerdonk, F.L., additional, Pickkers, P., additional, and ter Heine, R., additional
- Published
- 2020
- Full Text
- View/download PDF
42. Variabiliteit in farmacokinetiek van intraveneuze paracetamol bij gezonde ouderen
- Author
-
Mian, P. (Paola), van Esdonk, M.J., Winter, B.C.M. (Brenda) de, Spriet, I., Tibboel, D. (Dick), Petrovic, M. (Mirko), Allegaert, K.M. (Karel), Koch, B.C.P., Mian, P. (Paola), van Esdonk, M.J., Winter, B.C.M. (Brenda) de, Spriet, I., Tibboel, D. (Dick), Petrovic, M. (Mirko), Allegaert, K.M. (Karel), and Koch, B.C.P.
- Abstract
BACKGROUND and OBJECTIVE Paracetamol is the most used analgesic in older people. The physiological changes occurring with ageing influence the pharmacokinetics of paracetamol and its variability. A population pharmacokinetic analysis to describe the pharmacokinetics of intravenous paracetamol in fit older people was performed. Thereafter, simulations were conducted to illustrate target attainment and variability of paracetamol exposure following current dosing regimens (1000 mg q6h, q8h) using steady-state concentration (Css-mean) of 10 mg/L as target for effective analgesia. DESIGN and METHODS A population pharmacokinetic-analysis, using NONMEM 7.2, was performed based on 601 concentrations of paracetamol from 30 fit
- Published
- 2019
43. In Vitro Recovery of Sufentanil, Midazolam, Propofol, and Methylprednisolone in Pediatric Cardiopulmonary Bypass Systems
- Author
-
Saet, A. (Annewil) van, Zeilmaker-Roest, G.A. (Gerdien), Hoeven, M.P.J. (Marloes) van der, Koch, B.C.P. (Birgit), Rosmalen, J.M. (Joost) van, Kinzig, M. (Martina), Sorgel, F. (Fritz), Wildschut, E.D. (Enno), Stolker, R.J. (Robert), Tibboel, D. (Dick), Bogers, A.J.J.C. (Ad), Saet, A. (Annewil) van, Zeilmaker-Roest, G.A. (Gerdien), Hoeven, M.P.J. (Marloes) van der, Koch, B.C.P. (Birgit), Rosmalen, J.M. (Joost) van, Kinzig, M. (Martina), Sorgel, F. (Fritz), Wildschut, E.D. (Enno), Stolker, R.J. (Robert), Tibboel, D. (Dick), and Bogers, A.J.J.C. (Ad)
- Abstract
Objectives: To evaluate in vitro drug recovery in cardiopulmonary bypass (CPB) systems used for pediatric cardiac surgery. Design: Observational in vitro study. Setting: Single-center university hospital. Participants: In vitro CPB systems used for pediatric cardiac surgery. Interventions: Three full neonatal, infant, and pediatric CPB systems were primed according to hospital protocol and kept running for 6 hours. Midazolam, propofol, sufentanil, and methylprednisolone were added to the venous side of the systems in doses commonly used for induction of general anesthesia. Blood samples were taken from the postoxygenator side of the circuit immediately after injection of the drugs and after 2, 5, 7, 10, 30, 60, 180, and 300 minutes. Measurements and Main Results: Linear mixed model analyses were performed to assess the relationship between log-transformed drug concentration (dependent variable) and type of CPB system and sample time point (independent variables). The mean percentage of drug recovery after 60 and 180 minutes compared with T1 was 41.7% (95% confidence interval [CI] 35.9-47.4) and 23.0% (95% CI 9.2-36.8) for sufentanil, 87.3% (95% CI 64.9-109.7) and 82.0% (95% CI 64.6-99.4) for midazolam, 41.3% (95% CI 15.5-67.2) and 25.0% (95% CI 4.7-45.3) for propofol, and 119.3% (95% CI 101.89-136.78) and 162.0% (95% CI 114.09-209.91) for methylprednisolone, respectively. Conclusions: The present in vitro experiment with neonatal, infant, and pediatric CPB systems shows a variable recovery of routinely used drugs with significant differences between drugs, but not between system categories (with the exception of propofol). The decreased recovery of mainly sufentanil and propofol could lead to suboptimal dosing of patients during cardiac surgery with CPB.
- Published
- 2019
- Full Text
- View/download PDF
44. Emergency Department visits due to intoxications in a Dutch university hospital: Occurrence, characteristics and health care costs
- Author
-
Verheij, C. (C.), Rood, P.P.M. (Pleunie), Deelstra, C.K. (Carianne), Levendag, M.L.L. (M. L.L.), Koch, B.C.P. (Birgit), Polinder, S. (Suzanne), Klein Nagelvoort-Schuit, S.C.E. (Stephanie), Haagsma, J.A. (Juanita), Verheij, C. (C.), Rood, P.P.M. (Pleunie), Deelstra, C.K. (Carianne), Levendag, M.L.L. (M. L.L.), Koch, B.C.P. (Birgit), Polinder, S. (Suzanne), Klein Nagelvoort-Schuit, S.C.E. (Stephanie), and Haagsma, J.A. (Juanita)
- Abstract
Background: Intoxications with alcohol and drugs are common in the Emergency Department. This study aimed to describe the occurrence and characteristics of intoxications (alcohol, Drugs of Abuse (DOA), pharmaceutical and chemical) presented to the Emergency Department and the health care costs of these intoxications. Methods: This was a retrospective medical record study of all patients (≥ 16 years) who presented to the Emergency Department of an inner-city academic hospital in the Netherlands due to single or multiple intoxication(s) as the primary or secondary reason in the year 2016. An intoxication was reported as present if the attending physician described the intoxication in the patient's medical record. Results: A total of 783 patients were included, accounting for 3.2% of the adult Emergency Department population (age ≥ 16 year). In 30% more than one substance was used. Intoxications with alcohol, Drugs of Abuse and pharmaceuticals was reported in respectively 62%, 29% and 21% of the intoxicated patients. The mean costs per patient presenting with an intoxication to the Emergency Department was € 1,490. The mean costs per patient were highest for pharmaceutical intoxications (€ 2,980), followed by Drugs of Abuse (€ 1,140) and alcohol (€ 1,070). Conclusions: Intoxications among patients aged 16 years and older are frequently seen at the Emergency Department and are frequently caused by multiple substances. Alcohol is the most common intoxication. Substantial healthcare costs are involved. Therefore, this study suggests that further research into hazardous alcohol consumption and DOA abuse is warranted. Copyright
- Published
- 2019
- Full Text
- View/download PDF
45. Recovery of cefazolin and clindamycin in in vitro pediatric CPB systems
- Author
-
Zeilmaker-Roest, G.A. (Gerdien), Saet, A. (Annewil) van, Hoeven, M.P.J. (Marloes) van der, Koch, B.C.P. (Birgit), Rosmalen, J.M. (Joost) van, Kinzig, M. (Martina), Sorgel, F. (Fritz), Wildschut, E.D. (Enno), Stolker, R.J. (Robert), Tibboel, D. (Dick), Bogers, A.J.J.C. (Ad), Zeilmaker-Roest, G.A. (Gerdien), Saet, A. (Annewil) van, Hoeven, M.P.J. (Marloes) van der, Koch, B.C.P. (Birgit), Rosmalen, J.M. (Joost) van, Kinzig, M. (Martina), Sorgel, F. (Fritz), Wildschut, E.D. (Enno), Stolker, R.J. (Robert), Tibboel, D. (Dick), and Bogers, A.J.J.C. (Ad)
- Abstract
Cardiopulmonary bypass (CPB) is often necessary for congenital cardiac surgery, but CPB can alter drug pharmacokinetic parameters resulting in underdosing. Inadequate plasma levels of antibiotics could lead to postoperative infections with increased morbidity. The influence of pediatric CPB systems on cefazolin and clindamycin plasma levels is not kno
- Published
- 2019
- Full Text
- View/download PDF
46. Variability in pharmacokinetics of intravenous paracetamol in healthy older people Variabiliteit in farmacokinetiek van intraveneuze paracetamol bij gezonde ouderen
- Author
-
Mian, P. (Paola), Van Esdonk, M.J. (M. J.), Winter, B.C.M. (Brenda) de, Spriet, I. (Isabel), Tibboel, D. (Dick), Petrovic, M. (Mirko), Allegaert, K.M. (Karel), Koch, B.C.P. (Birgit), Mian, P. (Paola), Van Esdonk, M.J. (M. J.), Winter, B.C.M. (Brenda) de, Spriet, I. (Isabel), Tibboel, D. (Dick), Petrovic, M. (Mirko), Allegaert, K.M. (Karel), and Koch, B.C.P. (Birgit)
- Abstract
BACKGROUND and OBJECTIVE: Paracetamol is the most used analgesic in older people. The physiological changes occurring with ageing influence the pharmacokinetics of paracetamol and its variability. A population pharmacokinetic analysis to describe the pharmacokinetics of intravenous paracetamol in fit older people was performed. Thereafter, simulations were conducted to illustrate target attainment and variability of paracetamol exposure following current dosing regimens (1000 mg q6h, q8h) using steady-state concentration [Css-mean] of 10 mg/L as target for effective analgesia. DESIGN and METHODS: A population pharmacokinetic-analysis. using N0NMEM 7.2. was performed based on 601 concentrations of paracetamol from 30 fit older people (median age = 77.3 years [61.8-88.5], body weight = 79 kg 160-107)1. All had received an intravenous paracetamol dose of 1000 mg - over 15 min - after elective knee surgery. RESULTS: A two-compartment pharmacokinetic-model best described the data. Volume of distribution of paracetamol increased exponentially with body weight. Clearance was not influenced by any covariate. Simulations of the standardized dosing regimens resulted in a Css-mean of 9.2 mg/L Iq6h) and 7.2 mg/L Iq8h|. Variability in paracetamol pharmacokinetics resulted in a Css-mean above 5.4 (q6h| and 4.1 mg/L (q8h) in 90%. and above 15.5 Iq6h) and 11.7 mg/L Iq8h) in 10% of the population. CONCLUSION: The target concentration was achieved in the average patient with 1000 mg q6h, while q8h resulted in underdosing for the majority of the population. Due to large unexplained interindividual variability in paracetamol pharmacokinetics a relevant proportion of the fit older people remained either under- or overexposed.
- Published
- 2019
47. Assessing methods of measuring medication adherence in chronically ill children-a narrative review
- Author
-
Al-Hassany, L., Kloosterboer, S.M. (Sanne), Dierckx, B. (Bram), Koch, B.C.P. (Birgit), Al-Hassany, L., Kloosterboer, S.M. (Sanne), Dierckx, B. (Bram), and Koch, B.C.P. (Birgit)
- Abstract
Nonadherence in children who use long-term medication is a serious problem and assessing adherence is an important step to provide solutions to this problem. Medication adherence can be measured by several methods, including (a) self-report questionnaires or structured interviews, (b) therapeutic drug monitoring (TDM), (c) electronic devices, and (d) pick-up/refill rates. The objective of this narrative review is to provide an overview of the literature about methods for the measurement of medication adherence in chronically ill children and adolescents. Therefore, we conducted a literature search by using multiple databases. Four methods of monitoring medication adherence are presented for the most described chronic diseases: asthma, HIV/AIDS, epilepsy, diabetes mellitus and ADHD. First, 10 commonly used self-report questionnaires and structured interviews are described, including the main characteristics, (dis)advantages and their validation studies. Second, the use of TDM in pediatric trials for medication adherence measurement is discussed. New sampling methods (e.g. dried blood spot) and sampling matrices (e.g. hair, saliva and urine) have shown their benefits for TDM in children. Third, electronic devices to measure medication adherence in children are presented, being developed for several drug administration routes. Fourth, the analyses, advantages and disadvantages of pharmacy data are discussed. The usage of this data requires specific calculations and interpretations to assess adherence. As presented in this review, every adherence method has specific (dis)advantages. When deciding which adherence method is applicable, validity and generalizability should be taken into
- Published
- 2019
- Full Text
- View/download PDF
48. Population Pharmacokinetic Modeling of Acetaminophen and Metabolites in Children After Cardiac Surgery With Cardiopulmonary Bypass
- Author
-
Mian, R., Valkenburg, A.J. (Abraham), Allegaert, K.M. (Karel), Koch, B.C.P. (Birgit), Breatnach, C.V., Knibbe, C.A.J., Tibboel, D. (Dick), Krekels, EHJ, Mian, R., Valkenburg, A.J. (Abraham), Allegaert, K.M. (Karel), Koch, B.C.P. (Birgit), Breatnach, C.V., Knibbe, C.A.J., Tibboel, D. (Dick), and Krekels, EHJ
- Abstract
Children undergoing cardiac surgery often receive acetaminophen (paracetamol) as part of their postoperative pain treatment. To date, there is no information on the pharmacokinetics (PK) of acetaminophen in this special population, even though differences, as a result of altered hemodynamics and/or use of cardiopulmonary bypass, may be anticipated. Therefore, the aim of this study was to investigate the PK of intravenous acetaminophen in children after cardiac surgery with cardiopulmonary bypass. In the study, both children with and without Down syndrome were included. A population PK analysis, using NONMEM 7.2, was performed based on 161 concentrations of acetaminophen, acetaminophen sulfate, acetaminophen glucuronide, and oxidative metabolites from 17 children with Down syndrome and 13 children without Down syndrome of a previously published study (median age, 177 days [range, 92–944], body weight, 6.1 kg [4.0–12.9]). All children received 3 intravenous acetaminophen doses of 7.5 mg/kg (<10 kg) or 15 mg/kg (10 kg) at 8–hour intervals after cardiac surgery. For acetaminophen and its metabolites, 1-compartment models were identified. Clearance of acetaminophen and metabolites increased linearly with body weight. Acetaminophen clearance in a typical child of 6.1 kg is 0.96 L/h and volume of distribution 7.96 L. Down syndrome did not statistically significantly impact any of the PK parameters for acetaminophen, nor did any other remaining covariate.When comparing the PK parameters of acetaminophen in children after cardiac surgery with cardiopulmonary bypass with those from children of the same age following noncardiac surgery reported in the literature, clearance of acetaminophen was lower and volume of distribution higher.
- Published
- 2019
- Full Text
- View/download PDF
49. Placental effects and transfer of sildenafil in healthy and preeclamptic conditions
- Author
-
Hitzerd, E. (Emilie), Broekhuizen, M. (Michelle), Mirabito Colafella, K.M. (Katrina M.), Glisic, M. (Marija), Vries, R. (René) de, Koch, B.C.P. (Birgit), de Raaf, M.A. (Michiel A.), Merkus, D. (Daphne), Schoenmakers, S. (Sam), Reiss, I.K.M. (Irwin), Danser, A.H.J. (Jan), Simons, S.H.P. (Sinno), Hitzerd, E. (Emilie), Broekhuizen, M. (Michelle), Mirabito Colafella, K.M. (Katrina M.), Glisic, M. (Marija), Vries, R. (René) de, Koch, B.C.P. (Birgit), de Raaf, M.A. (Michiel A.), Merkus, D. (Daphne), Schoenmakers, S. (Sam), Reiss, I.K.M. (Irwin), Danser, A.H.J. (Jan), and Simons, S.H.P. (Sinno)
- Abstract
Background: The phosphodiesterase-5 inhibitor (PDE5) sildenafil has emerged as a promising treatment for preeclampsia (PE). However, a sildenafil trial was recently halted due to lack of effect and increased neonatal morbidity. Methods: Ex vivo dual-sided perfusion of an isolated cotyledon and wire-myography on chorionic plate arteries were performed to study the effects of sildenafil and the non-selective PDE inhibitor vinpocetine on the response to the NO donor sodium nitroprusside (SNP) under healthy and PE conditions. Ex vivo perfusion was also used to study placental transfer of sildenafil in 6 healthy and 2 PE placentas. Furthermore, placental mRNA and protein levels of eNOS, iNOS, PDE5 and PDE1 were quantified. Findings: Sildenafil and vinpocetine significantly enhanced SNP responses in chorionic plate arteries of healthy, but not PE placentas. Only sildenafil acutely decreased baseline tension in arteries of both healthy and PE placentas. At steady state, the foetal-to-maternal transfer ratio of sildenafil was 0·37 ± 0·03 in healthy placentas versus 0·66 and 0·47 in the 2 PE placentas. mRNA and protein levels of PDE5, eNOS and iNOS were
- Published
- 2019
- Full Text
- View/download PDF
50. Pharmacokinetic and pharmacodynamic considerations in the treatment of the elderly patient with hypertension
- Author
-
Peeters, L.E.J., primary, Kester, M.P., additional, Feyz, L., additional, Van Den Bemt, P.M.L.A., additional, Koch, B.C.P., additional, Van Gelder, T., additional, and Versmissen, J., additional
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.